Chia Ching Chen

CIDC Consultants, Inc. (CIDC Consultants) is an independent, Taiwan-based venture capital firm which was established in 1988 to offer management consulting, serve as an intermediary for domestic and foreign investment, facilitate investment-related technology cooperation, provide business intelligence and deliver inquiry services for venture capital firms. Located in Taipei, the firm manages funds backed by Taiwanese companies in a range of industries and works with European and American partners to make joint investments. CIDC has a cooperative relationship with Doughty Hanson & Co. and their affiliate, Global Financial Services, helps their investee companies to establish sound financial systems. ?

Part of China Development Financial Holding Corp., KGI Capital Asia Ltd. is a brokerage firm. The company is based in Hong Kong, Hong Kong. The CEO of the Chinese company is Pun Yuen Lam.

Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA.

TWi Pharmaceuticals Holding, Inc. provides pharmaceutical services.

StemCyte, Inc. operates as a biotechnology company that collects, banks and distributes cord blood stem cell transfusion units. It focuses on stem cell transplantation, therapy, applications, diagnostics, and genomic research. The firm uses insulated containers to keep your baby's cord blood cool throughout transport. The company was founded by Denis Rodgerson and Robert Chow in 1997 and is headquartered in Covina, CA.

Allgenesis Biotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company focused on researching and developing novel medicines for the treatment of eye diseases. The private company is based in Taipei, Taiwan. The company's current pipeline includes potential blockbuster drugs such as ag-73305 for the treatment of DME, NAMD, and other retinal diseases, as well as ag-80308 for dry eye disease. The company was founded by Chih Lung Shen and Chih Ming Chen. Madhu Cherukury has been the CEO of the company since 2014.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

KGI Securities Co., Ltd. provides securities broking, underwriting, and proprietary trading services. It also offers investment banking consultancy, warrants issuance, bonds conversion, fixed income trading, and wealth management services. Its products include derivatives, bond and equity options, mutual funds, and structured products. The company was founded on September 14, 1988 and is headquartered in Taipei, Taiwan.

The Development Center for Biotechnology of Taiwan is a nonprofit organization co-sponsored by government grants and private donations. It focuses on biotechnology and pharmaceutical industry. The company was founded in 1984 and is headquartered in Taipei, Taiwan.

China Investment & Development Co Ltd invests in Taiwan-based companies operating in the field of financial services. It provides financing for early and later stage capital requirements.

Sycamore Management Corp. (dba Sycamore Ventures) is an independent asset management firm headquartered in Princeton, New Jersey. The firm was founded in 1995 by Joseph Cho and Peter Gerry. Sycamore Ventures manages investment portfolios for individual and institutional clients.

Sycamore Ventures Pte Ltd. (Sycamore Ventures) is a private equity and venture capital subsidiary of Sycamore Management Corp., founded in 1995 by Mr. Kilin To, Mr. Peter Gerry, and the late Mr. John Whitman. The firm is headquartered in Princeton, New Jersey.

U-Systems, Inc. designs, develops, manufactures and markets ultrasound systems. The company was founded in 1997 and is headquartered in Schenectady, NY.

Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.